Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rangering i aksjer #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aksjekurs
$41.14
Sist synkronisert: 2026-09-21
Markedsverdi
$182.76B
Endring (1 dag)
-7.78%
Endring (1 år)
-32.24%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)

Kategori

Inntekter for Novo Nordisk A/S (NOVO-B)
Inntekter i Jun 2026 TTM: $23.62B
Ifølge Novo Nordisk A/S sine nyeste økonomiske rapporter er selskapets nåværende resultat $23.62B. I 2024 hadde selskapet et resultat på $17.75B, en økning sammenlignet med resultatet i 2023, som var $15.50B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Novo Nordisk A/S fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $23.62B 19.78%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$33.59B 42.24%
US
$25.20B 6.68%
US
$8.70B -63.17%
US
$21.39B -9.44%
CH
$5.95B -74.82%
US